Galectin Therapeutics Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA
pharmaceutical investing Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
pharmaceutical investing Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July